Our decades of proven success come from passionate team members around the globe collaborating to bring treatments forward. This may reduce waste and costs, optimize convenience and workflow and reduce the chance for preparation error-all of which support quality patient care.Įndo (OTC: ENDPQ) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Ready-to-use, or RTU, products streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. In April, Endo executed an agreement with Slayback Pharma LLC to distribute PREVDUO ™ on an exclusive basis in the U.S. Neostigmine is always administered in conjunction with glycopyrrolate and, until now, its administration has required two syringes. as single, active ingredient drug products. "With two medications in one ready-to-use syringe, PREVDUO ™ reduces complexity and increases efficiency for hospitals and healthcare providers."īoth neostigmine methylsulfate and glycopyrrolate have been approved in the U.S. Needham is upbeat on Sunrun because of its leading market position in the solar industry, while it has near-term concerns about profit margin pressures for First Solar."This is the latest way we're addressing operational and clinical challenges in order to support patient care," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. Sunrun was rated "buy" in new coverage at Needham, and the firm initiated coverage on First Solar with a "hold" rating. Sunrun (RUN), First Solar (FSLR) – Sunrun rose 2.8% in premarket trading, while First Solar added 1.1%. Take-Two maintained its prior full-year outlook and shares fell 1.9% in the premarket. Take-Two Interactive (TTWO) – Take-Two is delaying new versions of its "Grand Theft Auto" video game by four months, saying it wants additional time to "further polish" the final products. The maker of streetwear and action sports apparel did not provide an outlook, due to volatile market conditions, and shares fell 5.3% in premarket trading. Zumiez (ZUMZ) – Zumiez beat estimates by 23 cents with adjusted quarterly earnings of $1.02 per share, but revenue fell short of the consensus view. It projects full-year earnings of $2.02 to $2.26 compared with a $2.24 consensus estimate. The maker of outdoor recreational products got a boost from increased profit margins and higher sales in both domestic and international markets. It expects that to continue, barring any significant Covid-related downturn.Īmerican Outdoor Brands (AOUT) – American Outdoor Brands earned an adjusted 48 cents per share for its fiscal first quarter, 8 cents above estimates. The restaurant and arcade chain's revenue beat Wall Street forecasts and Dave & Buster's said it continues to see signs of recovery in its business. Nielsen shares rose 1.3% in the premarket.ĭave & Buster's (PLAY) – Dave & Buster's rallied 7.9% in premarket trading after it reported quarterly earnings of $1.07 per share, well above the 58-cent consensus estimate. Nielsen Holdings (NLSN) – Nielsen CEO David Kenny defended the ratings company in a letter to TV industry executives and said Nielsen does need to move faster in adjusting its ratings systems to capture the consumer shift from traditional viewing to streaming. Wells Fargo shares added 2% in premarket action. Regulators had first identified those issues in a 2018 order. Wells Fargo (WFC) – Wells Fargo was fined $250 million by regulators who said the bank has not made sufficient progress in solving ongoing issues in its mortgage business. Bausch had been accused of illegally maintaining a monopoly on the treatment, with the price increasing nearly 800% in 2015. Toyota gained 1.1% in the premarket.Įndo International (ENDP) – Endo surged 19.1% in premarket action after it agreed to pay $50 million to resolve lawsuits by New York State and two counties over the drug maker's sale and marketing of opioids.īausch Health (BHC) – Bausch Health will pay $300 million to settle an antitrust lawsuit involving the company's diabetes drug Glumetza. Toyota Motor (TM) – The automaker cut its annual production target by 300,000 vehicles as factories in Vietnam and Malaysia were hit by the spread of Covid-19 and the ongoing computer chip shortage. Personal Loans for 670 Credit Score or Lower Personal Loans for 580 Credit Score or Lower Best Debt Consolidation Loans for Bad Credit
0 Comments
Leave a Reply. |